HOME >> BIOLOGY >> NEWS
Trial found no impact of Malarone(TM) on performance and alertness tasks

Results from a new study presented today at the 75th Annual Scientific Meeting of the Aerospace Medical Association (AsMA) in Anchorage, USA, suggest that MalaroneTM (atovaquone and proguanil hydrochloride) would not be expected to affect the ability of pilots and cabin crew to perform their duties while on an aircraft (1). The risk of developing clinical malaria for aircrew flying to highly endemic regions is estimated at 0.5 per 1000 persons per overnight stay (2). Considerable periods of incapacity and fatal cases in aircrew have been reported (3).

The study is the first to assess side effects of an antimalarial drug in a hypobaric chamber at aircraft cabin pressure (75.2kPa), and the results showed that clinically effective levels of MalaroneTM [250mg atovaquone + 100 mg proguanil HCl] were well tolerated and had no significant effect on vigilance, alertness, processing complex information, sleepiness and duration or quality of sleep for the volunteers.

"Use of medication for aircrew on duty is prohibited by national law and international rules, unless convincing evidence can be provided that the treatment in question has no negative effects on performance and alertness. Therefore, we submitted these data to the Civil Aviation Authorities of The Netherlands and the Joint Aviation Authorities of Europe for their consideration to recommend the use of MalaroneTM in pilots and cabin crew," said Dr Ries Simons of the TNO Human Factors Institute, Soesterberg, The Netherlands.

The randomized double-blind cross-over study involved 22 healthy volunteers who received MalaroneTM or placebo for a 14 day period, and underwent rigorous performance testing while in a hypobaric chamber that was pressurized to the minimum pressure for commercial airlines. This included tests developed by NASA to assess performance and alertness tasks similar to activities that aircraft crew members perform in-f
'"/>

Contact: Heather Bell
heather_bell@uk.bm.com
44-207-300-6319
Burson-Marsteller
6-May-2004


Page: 1 2

Related biology news :

1. Trial shows which brain cancer patients benefit from temozolomide
2. Trial drugs for Huntingtons disease inconclusive in slowing disease
3. National Institute on Drug Abuse launches National Drug Addiction Treatment Clinical Trials Network
4. Immunex And Wyeth-Ayerst Laboratories Advance Enbrel Into Phase II/III Clinical Trial For Chronic Heart Failure
5. Gene Therapy Trial Approved For Rare Anemia
6. Severe Pain Following Shingles Safely Relieved In Clinical Trial Of Anti-Convulsant Drug Gabapentin
7. Cardiac Clinical Trial Studies Use of Antibiotic In Preventing Heart Attack
8. Clinical Trials Show That Bone Marrow Transplant And Vitamin A Derivative Both Improve Survival From Neuroblastoma
9. Novel Drug Trial To Treat Advanced Prostate Cancer Enrolling Patients At UCSF/Mount Zion Cancer Center
10. Targeted Genetics, M.D. Anderson Cancer Center And University Of Pittsburgh Report Phase I Clinical Trial Results Of Gene Therapy Treatment For Cancer
11. Experimental Trial Combines DNA Vaccine With Triple-Drug Therapy To Stop HIV

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/16/2019)... , ... June 14, 2019 , ... ... Oracle Cloud customer, will deliver a joint presentation with Versiti’s CIO at the ... 16-19 at the Rosen Shingle Creek Resort. , Versiti Vice President and Chief ...
(Date:6/11/2019)... Ind. (PRWEB) , ... June 10, 2019 , ... Improved ... in the July 2019 issue of AAPS PharmSciTech. The article was published online on ... of Improved Pharma, along with Xiaoming Sean Chen of Purdue University. , The ...
(Date:6/4/2019)... Calif. (PRWEB) , ... June 04, 2019 , ... ... technologies, today announced the appointment of Susan Murphy as the new President of ... Life Sciences?owned by Molecular Devices’ parent company, Danaher Corporation. , Since joining Molecular ...
Breaking Biology News(10 mins):
(Date:6/11/2019)... (PRWEB) , ... June 11, 2019 , ... ... engagement, and Carilion Clinic, a national leader in opioid treatment, announced today they ... care. , Mytonomy recently deployed its virtual care platform at the ...
(Date:6/11/2019)... ... June 11, 2019 , ... ... from human mesenchymal stem cells (MSC-EV) are able to incorporate into human CD34+ ... a test on mice, MSC-EVs also increased the cells’ ability to lodge into ...
(Date:5/31/2019)... ... ... For many years, the primary forms of cancer treatment have been chemotherapy, radiation ... have led to the advent of Chimeric Antigen Receptor T (CAR T) cell therapy, ... “CARs”. The CAR enables the final product to produce chemicals in the hopes that ...
(Date:5/31/2019)... ... 2019 , ... World Compliance Seminars today announced a live ... Boston, MA. This peer recommended interactive workshop is always selected by professionals at ... off with a compendial treatment of Data Integrity fundamentals. After laying the groundwork, ...
Breaking Biology Technology:
Cached News: